Robinson 2000a.

Study characteristics
Methods	Parallel design Comparison of fluoxetine, nortriptyline and placebo. We are using the fluoxetine and placebo data Analysis: per protocol, number excluded from analyses varied Data provided for depressed and non‐depressed separately. We are labelling the depressed group as Robinson 2000a (this trial), and the non‐depressed group as Robinson 2000b
Participants	Location: USA and Argentina Setting: mixed Treatment: 23 people with depression, mean ± SD age 65 ± 14 years; 17 men Control: 17 people with depression, mean ± SD age 73 ± 10 years; 9 men Stroke criteria: all subtypes, diagnosis by clinical signs and CT (100%), stroke within 6 months of recruitment, 18 to 85 years of age Stroke on average 16 weeks (fluoxetine) and 6 weeks (placebo) prior to randomisation Exclusion criteria: other significant medical illness, severe comprehension deficit, prior history of head injury, prior history of other brain disease (with the exception of stroke), participants on antidepressants (other than fluoxetine) were allowed to stop their antidepressant for a 2‐week washout period
Interventions	Treatment: fluoxetine 10 mg daily (3 weeks), 20 mg daily (3 weeks), 30 mg daily (3 weeks), 40 mg daily (3 weeks) Control: matched placebo Duration: treatment continued for 12 weeks Duration of follow‐up (end of treatment to end of study): 0
Outcomes	Depression: change in scores from baseline to end of treatment on HDRS Additional: MMSE, JHFI Death AEs (method of reporting these was not stated)
Funding source	Funded by NIMH grants and grants from the Raul Carrea Institute of Neurological Research and Fundacion Perez Companc. Eli Lilly and company supplied the fluoxetine and placebo
Notes	Note difference in time since stroke between treatment groups Dates of recruitment not stated. Conflicts not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random‐number table
Allocation concealment (selection bias)	Low risk	Concealment held by independent person
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Matched placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	Per‐protocol and ITT analyses
Selective reporting (reporting bias)	Low risk	Protocol published www.strokecentre.org/trials
Other bias	Unclear risk	Imbalance in treatment groups for time since stroke and gender